| Bioactivity | SWS1 is a d-(+)-biotin-conjugated PD-L1 inhibitor (IC50: 1.8 nM) with anticancer activity. SWS1 can increase the number of tumor-infiltrating lymphocytes and exhibit anti-tumor efficacy in the B16-F10 mouse model (TGI=66.1%)[1]. |
| Target | IC50: 1.8 nM (PD-1/PD-L1) |
| Name | SWS1 |
| CAS | 2922115-32-8 |
| Formula | C47H53ClN6O5S |
| Molar Mass | 849.48 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ding Z, et al. Discovery of Novel d-(+)-Biotin-Conjugated Resorcinol Dibenzyl Ether-Based PD-L1 Inhibitors for Targeted Cancer Immunotherapy. J Med Chem. 2023 Aug 10;66(15):10364-10380.. |